Cartesian Therapeutics (RNAC) Reports Durable Myasthenia Gravis Retreatment Data for Descartes-08

Cartesian Therapeutics (RNAC) on Sept. 29 reported additional retreatment data for its investigational CAR-T therapy Descartes-08, showing sustained symptom improvements in patients with generalized myasthenia gravis. Shares closed at $7.21, down 2.70%. In a Phase 2 case series of five patients retreated after symptom recurrence, the mean MG-ADL score improved by 6.6 points at 12 months post-retreatment, with a median retreatment interval of 16.6 months. No new safety signals emerged; no serious adverse events, cytokine release syndrome or neurotoxicity occurred during retreatment. Descartes-08 is an autologous CAR-T therapy targeting BCMA, under development for MG and myositis. Cartesian expects topline Phase 3 AURORA data in the first quarter of 2027.